The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder Cancer
Bas W.G. van Rhijn(The Netherlands Cancer Institute), Bharati Bapat(Mount Sinai Hospital), Michael A.S. Jewett(Princess Margaret Cancer Centre), Ellen C. Zwarthoff(Erasmus MC), Theodorus van der Kwast(Erasmus MC), Neil Fleshner(University of Toronto), André N. Vis(Hôpitaux Universitaires Henri-Mondor), Peter J. Boström(University of Turku), Chris H. Bangma(Erasmus University Rotterdam), Sultan S. Alkhateeb(Princess Margaret Cancer Centre), Liyang Liu(Mount Sinai Hospital), Alexandre R. Zlotta(Mount Sinai Hospital)
Cited by 102
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654